RABS and Advanced Aseptic Processing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

RABS and Advanced Aseptic Processing


Pharmaceutical Technology


For at least 20 years, the global parenteral industry has recognized that personnel are the dominant risk relative to microbial contamination in aseptically produced sterile products (1). The contamination source strength of the gowned aseptic processing operator has been estimated in several research studies. Concomitant with this awareness, we have witnessed a series of technological advances that have endeavored to mitigate this contamination risk. These advances can be roughly categorized as follows:

  • separate personnel from the aseptic environment;
  • limit personnel interaction with sterile materials;
  • remove personnel from the aseptic environment;
  • some combination of the above.



Each of these approaches provides some added measure of security to the process by increasing the degree of separation provided between personnel and the sterilized materials, components, and product contact surfaces required for the aseptic assembly of the sterile product from its individual elements.

Advanced versus conventional aseptic processing

To the extent that these approaches are effective, they can reduce contamination risk in aseptic processing. Designs that most effectively eliminate human-borne contamination have been identified as providing "advanced aseptic processing." The term advanced aseptic processing was perhaps first used at the USP Open Conference on Microbiology in May 2002 (2). During that conference, only two aseptic technologies were discussed under the heading of "advanced": isolators and blow–fill–seal. Over the intervening years, we have witnessed the term advanced aseptic processing come into ever wider use. Considering the goals of aseptic processing, that other technologies intended to meet the high expectations for sterile product manufacturing aseptically should emerge is unremarkable.

Several technical features distinguish advanced from conventional aseptic processing. We believe the following condition should be met for an aseptic processing technology to be considered advanced: no interventions should be conducted during aseptic operations by gowned employees. In other words, all interventions must be conducted using separative features such as isolator gloves or half-suits. Obviously, this condition also could be met if manned interventions of any type were not required—as can be the case in blow–fill–seal or gloveless isolators. The contamination potential from the human operator, even under the most ideal conditions, is such that the aseptic process may be compromised by even a single manipulation by gowned personnel in proximity to the sterile materials. At a minimum, the allowance of limited human interventions creates risk uncertainty that we believe is incompatible with the concept of advanced aseptic processing.

A historical perspective


Figure 1: Aseptic processing family tree.
A brief historical review of the environmental systems used for aseptic processing is useful to understand the genesis of today's processing technologies (see Figure 1).

Perhaps little known to many current practitioners is the previous use of gloveboxes for aseptic processing before the introduction of cleanroom technology. Clearly, the early practitioners of aseptic processing understood the risk from human-borne contamination and used physical separation between the operator and the so-called sterile field to provide greater control over microorganisms.

The emergence of the HEPA filter in the mid 1950s changed facility designs and operating practices dramatically. It was now possible to position equipment inside a room and, using gowned personnel, produce larger numbers of units with less human manipulation. This design has continued to evolve to the more advanced barrier designs we see today. Gloveboxes never became obsolete, but labor requirements, throughput limitations, decontamination constraints, and other factors limited their application in aseptic processing.

The cleanroom dominated the industry as the preferred choice for aseptic processing because it was amenable to high-speed filling, inclusion of processing equipment, and easy adaptation for various applications. Later designs included partial barriers to provide greater separation between operators and sterile materials.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Pharmaceutical Technology,
Click here